Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin

American Heart Journal

Volumn 148, Issue 3, 2004, Pages 447-455

  Stein, Evan ^a   Stender, Steen ^b   Mata, Pedro ^c   Sager, Philip ^d   Ponsonnet, Damien ^d   Melani, Lorenzo ^d   Lipka, Leslie ^d   Suresh, Ramachandran ^d   MacCubbin, Darbie ^d   Veltri, Enrico ^d  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TITRIMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; TRIGLYCERIDES;

EID: 4644256971     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.052     Document Type: Article

References (27)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
2. Shepherd J. Preventing coronary artery disease in the West of Scotland implications for primary prevention. Am J Cardiol. 82:1998;57-59T
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomized placebo-controlled trial. Lancet. 360:2002;7-22
4. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third Report of the National Cholesterol Education Program (NCEP). JAMA. 285:2001;2486-2497
5. de Backer G., Ambrosini E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice executive summary of the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil. 10:2003;S1-10
6. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 347:2001;995-1001
7. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160:2000;459-467
8. Frolkis J.P., Zyzanski S.J., Schwartz J.M., et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 98:1998;851-855
9. Stein E.A. An investigative look selective cholesterol absorption inhibitors - embarking on a new standard of care. Am J Manag Care. 8:(Suppl 2):2002;S36-39
10. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
11. van Heek M., Farley C., Compton D.S., et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 129:2000;1748-1754
12. van Heek M., Farley C., Compton D.S., et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 134:2001;409-417
13. Gagne C., Gaudet D., Bruckert E., et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 105:2002;2469-2476
14. Gagne C., Bays H., Weiss S., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1084-1091
15. Davidson M., McGarry T., Bettis R., et al. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134
16. Kerzner B., Corbelli J., Sharp S., et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 91:2003;418-424
17. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial. Circulation. 107:2003;2409-2415
18. Melani L., Mills R., Hassman D., et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia a prospective, randomized, double-blind trial. Eur Heart J. 24:2003;717-728
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023
20. Myers G.L., Cooper G.R., Winn C.L., et al. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements. Clin Lab Med. 9:1989;105-135
21. Lipid Research Clinics Program. Manual of operations lipid and lipoprotein analysis (publication NIH 75-628). 1982;US Department of Health, Education and Welfare, Washington, DC
22. Steiner P., Freidel J., Bremmer W., et al. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. J Clin Chem. 19:1981;850-851
23. Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76
24. Heinonen T.M., Stein E.A., Weiss S.R., et al. The lipid lowering effects of atorvastatin, a new HMG CoA reductase inhibitor results of a randomized, double-masked study. Clin Ther. 18:1996;853-863
25. Stein E.A., Strutt K., Southworth H., et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 92:2003;1287-1293
26. Thompson G.R. Familial hypercholesterolemia. Betteridge D.J., Illingworth D.R., Shepherd J. Lipoproteins in health and disease. 1999;675-692 Edward Arnold, London
27. Jacobson T.A., Griffiths G.G., Varas C., et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid lowering therapy based on updated NHANES III data. Arch Intern Med. 160:2000;1361-1369